Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sri Lanka approves Pfizer COVID vaccine for emergency use

05/08/2021 | 04:55am EDT
FILE PHOTO: Syringes are seen at the Impfzentrum Basel Stadt vaccination center in Basel

COLOMBO (Reuters) - Sri Lanka on Saturday approved Pfizer's COVID-19 vaccine for emergency use in Sri Lanka, as the island nation battles a third wave of the virus, while suffering a restricted supply of vaccines from neighboring India.

Dr. Sudharshani Fernandopulle, the minister overseeing the fight against the epidemic, said in a statement the government would order 5 million doses of the Pfizer vaccine.

Sri Lanka is seeking to secure other vaccines as the Serum Institute of India, the world's largest vaccine manufacturer, has suspended the delivery of AstraZeneca's Covishield vaccine due to spiraling coronavirus infections in India.

Sri Lanka is the first country in South Asia to approve the Pfizer vaccine. It has also approved Russia's Sputnik and China's Sinopharm vaccines for emergency use.

The island nation reported 1,914 new cases and 19 deaths in the past 24 hours, according to federal health data, and its total number of active cases is higher than any point since the pandemic began. Infections surged after crowded celebrations for traditional New Year last month.

(Reporting by Waruna Karunatilake in Colombo; Writing by Alasdair Pal)

By Waruna Karunatilake


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.37% 8352 Delayed Quote.14.47%
PAL GROUP HOLDINGS CO., LTD. -0.88% 1687 End-of-day quote.38.17%
PFIZER, INC. -1.70% 38.81 Delayed Quote.5.43%
SINOPHARM GROUP CO., LTD. -4.25% 22.55 End-of-day quote.19.57%
All news about ASTRAZENECA PLC
06/19ASTRAZENECA  : pringsteen on Broadway' clears way for AstraZeneca recipients to ..
AQ
06/18ASTRAZENECA  : Argentine lab makes first half million doses of Russian COVID-19 ..
RE
06/18Ontarians cancelling AZ doses after new guidance, province still offering dos..
AQ
06/18Health Care Down Amid Defensive Bias -- Health Care Roundup
DJ
06/18U.S.-CANADA BORDER COULD REOPEN TO F : Legault
AQ
06/18Eurostoxx 50 : European shares deepen losses after hawkish Fed comments
RE
06/18THE LATEST : Brazil to hit 500K deaths, 2nd highest globally
AQ
06/18ASTRAZENECA  : Ordered by Brussels Court to Deliver 80.2 Million COVID-19 Jabs t..
MT
06/18ASTRAZENECA  : claims victory over EU in vaccine deliveries case
AQ
06/18ASTRAZENECA  : EU both claim a win in vaccine delivery tussle
AQ
More news
Financials (USD)
Sales 2021 30 966 M - -
Net income 2021 4 588 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,5x
Yield 2021 2,47%
Capitalization 152 B 152 B -
EV / Sales 2021 5,25x
EV / Sales 2022 4,49x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,03 $
Last Close Price 115,73 $
Spread / Highest target 47,7%
Spread / Average Target 14,9%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%151 865
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795